Amarin Makes Flawed Argument In Bid To Drain Omega-3 Market – CRN

CRN recommends the International Trade Commission not investigate Amarin's complaint against dietary supplements containing primarily ethyl ester or re-esterified EPA. The firm markets Vascepa, a synthetically produced ethyl ester drug approved to reduce triglyceride levels in adults with severe hypertriglyceridemia.

Gavel

The drug firm challenging the US omega-3 dietary supplement market in a fair trade complaint admits that FDA finds the products entirely compliant with its regulations and makes a repeatedly dismissed argument for its false advertising claim, says the Council for Responsible Nutrition.

In comments its attorneys submitted Sept. 14 to the International Trade Commission, the trade group also recommended the Department of...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Legal

More from Policy & Regulation